Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

Medically reviewed by Anju Goel, MD Key Takeaways People with polycythemia vera should not skip phlebotomy appointments to manage their condition.People with blood disorders like PV may have a higher ...

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

Rusfertide showed a 77% clinical response rate in polycythemia vera patients, significantly higher than the 33% with placebo. The drug reduced phlebotomy frequency, with 0.5 per patient in the ...

Findings showed 77% of PV patients treated with rusfertide achieved a clinical response compared with 33% of those who received placebo. Topline data were announced from a phase 3 trial evaluating ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy. The data ...

DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia vera a few years ago. I understand this variety of polycythemia isn’t caused by smoking, but we know that smoking does make it ...